Key Developments: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

3.27USD
31 Oct 2014
Price Change (% chg)

$-0.02 (-0.61%)
Prev Close
$3.29
Open
$3.35
Day's High
$3.40
Day's Low
$3.24
Volume
444,177
Avg. Vol
395,249
52-wk High
$4.17
52-wk Low
$1.65

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sequenom purchases noninvasive prenatal testing intellectual property from Isis Innovation
Monday, 6 Oct 2014 04:30pm EDT 

Sequenom Inc:Says the company and Isis Innovation Ltd jointly announced that Sequenom has purchased noninvasive prenatal testing intellectual property from Isis Innovation, for $14.55 mln.Under the terms of the agreement, Sequenom is now the owner of global intellectual property for noninvasive prenatal genetic diagnostic testing on paternally inherited fetal nucleic acids derived from maternal plasma or serum.Purchase price includes $3.2 mln as the final royalty payment due to Isis under the prior agreement and the waiver of $2.1 million in paid legal fees that Isis owed to Sequenom, with additional downstream payments contingent on revenues exceeding certain thresholds.  Full Article

Nicox and Sequenom announces launch of expanded access to RetnaGene test portfolio in the U.S
Thursday, 19 Jun 2014 07:00am EDT 

Sequenom Inc:Nicox and Sequenom announces that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(tm) portfolio of laboratory-developed genetic tests in the United States (U.S.).RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration.  Full Article

Sequenom receives U.S. FDA premarket clearance
Monday, 16 Jun 2014 08:00am EDT 

Sequenom Inc:Receives premarket 510(k) clearance from the United States Food and Drug Administration (FDA) to market its IMPACT Dx Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx System.IMPACT Dx Factor V Leiden and Factor II Genotyping Test is performed on the IMPACT Dx System, and is indicated for use as an aid in the diagnosis of patients with suspected thrombophilia.  Full Article

Sequenom Laboratories and Quest Diagnostics collaborate to expand patient access to the MaterniT21 PLUS Noninvasive Prenatal Test
Monday, 16 Jun 2014 08:00am EDT 

Sequenom Inc and Quest Diagnostics Inc:Announces an agreement under which Quest will offer national access to Sequenom Laboratories' MaterniT21 PLUS laboratory-developed test.Quest expects to begin offering access to the test in the third quarter.Also Quest has formed a license agreement with Sequenom for certain NIPT patents and patent applications.License agreement is the first formed by Sequenom with a commercial lab in the United States.Quest intends to use the intellectual property for the purposes of developing and validating its own lab-developed NIPT test.  Full Article

Sequenom Inc's Sequenom laboratories announces national coverage agreement for prenatal diagnostic testing services
Monday, 9 Jun 2014 07:00am EDT 

Sequenom Inc:Says its wholly owned subsidiary, Sequenom Laboratories signs national agreement with health insurance company covering 13 mln people throughout United States.Says to provide MaterniT21 PLUS laboratory-developed test (LDT).Addition of this contract brings number of covered lives under agreement by Sequenom Laboratories' diagnostic services to more than 140 mln.  Full Article

Sequenom Inc's bioscience business acquired by Agena Bioscience
Friday, 30 May 2014 04:30pm EDT 

Sequenom Inc:Says Agena Bioscience, Inc, a portfolio company of Telegraph Hill Partners (THP) acquired the Bioscience business of the company.Agena Bioscience has retained the employees of the acquired segment and will remain headquartered in San Diego, California.  Full Article

Sequenom Inc announces chief executive officer and chief financial officer changes
Wednesday, 5 Mar 2014 07:00pm EST 

Sequenom Inc:Says that Harry F. Hixson, Jr. will retire as chief executive officer (CEO), effective as of the company's 2014 annual meeting on June 10.William J. Welch, the company's current president and chief operating officer, will assume the role of CEO, effective as of the annual meeting and immediately upon Hixson's retirement as CEO.In addition, Paul V. Maier, chief financial officer (CFO) since 2009, will retire effective as of the annual meeting.Maier will serve as consultant to the company following his retirement.Carolyn D. Beaver, current vice president and chief accounting officer, will assume the role of CFO, effective as of the annual meeting and immediately upon Maier's retirement as CFO.  Full Article

Sequenom Inc's Sequenom Laboratories grants NicOx SA exclusive promotion and marketing rights for its RetnaGene AMD test in North America
Thursday, 16 Jan 2014 01:30am EST 

NicOx SA and Sequenom Inc:Say that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field.Say Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years.  Full Article

Sequenom Inc announces issuance of European patent for novel methods of detecting fetal aneuploidy
Wednesday, 8 Jan 2014 05:24pm EST 

Sequenom Inc:Says on Jan. 1, 2014, the European Patent Office (EPO) issued patent EP2183693 B1, entitled Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing, invented by Drs Dennis Lo, Rossa Chiu, and Kwan Chee Chan of The Chinese University of Hong Kong.Says the patent claims novel methods for detecting fetal aneuploidy using sequencing and was the first patent filing made in the EPO directed to such novel methods.Says it holds exclusive rights to the patent, an important part of Sequenom's prenatal diagnostic patent portfolio, with coverage across all countries in the European Union, and also including Liechtenstein, Monaco, Norway and Switzerland.  Full Article

Harwood Feffer LLP Announces Investigation Of Sequenom Inc
Tuesday, 10 Sep 2013 10:02am EDT 

Harwood Feffer LLP announced that it is investigating potential claims against the board of directors of Sequenom Inc, concerning whether the board has breached its fiduciary duties to shareholders. The investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.  Full Article

Search Stocks